Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04296890
Registration number
NCT04296890
Ethics application status
Date submitted
27/02/2020
Date registered
5/03/2020
Date last updated
25/07/2023
Titles & IDs
Public title
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Query!
Scientific title
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Query!
Secondary ID [1]
0
0
2020-000179-19
Query!
Secondary ID [2]
0
0
IMGN853-0417
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SORAYA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Epithelial Ovarian Cancer
0
0
Query!
Peritoneal Cancer
0
0
Query!
Fallopian Tube Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Ovarian and primary peritoneal
Query!
Cancer
0
0
0
0
Query!
Womb (Uterine or endometrial cancer)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Mirvetuximab Soravtansine
Experimental: Treatment - All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
Treatment: Drugs: Mirvetuximab Soravtansine
Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor a (FRa). It consists of the humanized anti-FRa mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the Investigator.
Query!
Timepoint [1]
0
0
Up to 2 years
Query!
Secondary outcome [1]
0
0
Duration of Response (DOR)
Query!
Assessment method [1]
0
0
The time from initial Investigator-assessed response (CR or PR) until progressive disease (PD) as assessed by the Investigator
Query!
Timepoint [1]
0
0
Up to 2 years
Query!
Secondary outcome [2]
0
0
Adverse Events (AEs)
Query!
Assessment method [2]
0
0
Adverse Events (AE's) will be evaluated according to the NCI CTCAE v5.0. AE's will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term (PT).
Query!
Timepoint [2]
0
0
Up to 2 years
Query!
Secondary outcome [3]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [3]
0
0
The time from first dose of MIRV until Investigator-assessed radiological progressive disease (PD) or death, whichever occurs first.
Query!
Timepoint [3]
0
0
Up to 2 years
Query!
Secondary outcome [4]
0
0
Overall Survival (OS)
Query!
Assessment method [4]
0
0
The time from first dose of MIRV until death.
Query!
Timepoint [4]
0
0
Up to 2 years
Query!
Secondary outcome [5]
0
0
CA-125 Response
Query!
Assessment method [5]
0
0
Serum CA-125 response determined using the Gynecologic Cancer Intergroup (GCIG) criteria.
Query!
Timepoint [5]
0
0
Up to 2 years
Query!
Eligibility
Key inclusion criteria
1. Female patients = 18 years of age
2. Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian
cancer (EOC), primary peritoneal cancer, or fallopian tube cancer
3. Patients must have platinum-resistant disease:
1. Patients who have only had 1 line of platinum based therapy must have received at
least 4 cycles of platinum, must have had a response (complete response/remission
(CR) or partial response/remission (PR)) and then progressed between > 3 months
and = 6 months after the date of the last dose of platinum
2. Patients who have received 2 or 3 lines of platinum therapy must have progressed
on or within 6 months after the date of the last dose of platinum
Note: Progression should be calculated from the date of the last administered dose of
platinum therapy to the date of the radiographic imaging showing progression
Note: Patients who are platinum refractory during front-line treatment are excluded
(see exclusion criteria)
4. Patients must have progressed radiographically on or after their most recent line of
anticancer therapy.
5. Patients must be willing to provide an archival tumor tissue block or slides, or
undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure
for immunohistochemistry (IHC) confirmation of Folate Receptor a (FRa) positivity
6. Patient's tumor must be positive for FRa expression as defined by the Ventana FOLR1
Assay
7. Patients must have at least 1 lesion that meets the definition of measurable disease
by RECIST v1.1 (radiologically measured by the Investigator)
8. Patients must have received at least 1 but no more than 3 prior systemic lines of
anticancer therapy, including at least 1 line of therapy containing bevacizumab, and
for whom single-agent therapy is appropriate as the next line of treatment:
1. Adjuvant ± neoadjuvant considered 1 line of therapy
2. Maintenance therapy (e.g., bevacizumab, poly adenosine diphosphate-ribose
polymerase (PARP) inhibitors) will be considered part of the preceding line of
therapy (i.e., not counted independently)
3. Therapy changed due to toxicity in the absence of progression will be considered
part of the same line (i.e., not counted independently)
4. Hormonal therapy will be counted as a separate line of therapy unless it was
given as maintenance
9. Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS)
of 0 or 1
10. Patients must have completed prior therapy within the specified times below:
1. Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is
shorter) prior to first dose of MIRV
2. Focal radiation completed at least 2 weeks prior to first dose of MIRV
11. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior
therapy-related toxicities (except alopecia)
12. Patients must have completed any major surgery at least 4 weeks prior to first dose of
MIRV and have recovered or stabilized from the side effects of prior surgery
13. Patients must have adequate hematologic, liver and kidney functions defined as:
1. Absolute neutrophil count (ANC) = 1.5 x 10^9/L (1,500/µL) without G-CSF in the
prior 10 days or long-acting WBC growth factors in the prior 20 days
2. Platelet count = 100 x 10^9/L (100,000/µL) without platelet transfusion in the
prior 10 days
3. Hemoglobin = 9.0 g/dL without packed red blood cell (PRBC) transfusion in the
prior 21 days
4. Serum creatinine = 1.5 x upper limit of normal (ULN)
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x ULN
6. Serum bilirubin = 1.5 x ULN (patients with documented diagnosis of Gilbert
syndrome are eligible if total bilirubin < 3.0 x ULN)
7. Serum albumin = 2 g/dL
14. Patients or their legally authorized representative must be willing and able to sign
the informed consent form (ICF) and to adhere to the protocol requirements
15. Women of childbearing potential (WCBP) must agree to use highly effective
contraceptive method(s) (as defined in Section 5.8.6 of the protocol) while on MIRV
and for at least 3 months after the last dose
16. WCBP must have a negative pregnancy test within the 4 days prior to the first dose of
MIRV
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Male patients
2. Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed
tumors containing any of the above histologies, or low-grade/borderline ovarian tumor
3. Patients with primary platinum-refractory disease, defined as disease that did not
respond to (CR or PR) or has progressed within 3 months of the last dose of first-line
platinum-containing chemotherapy
4. Patients with prior wide-field radiotherapy (RT) affecting at least 20 percent of the
bone marrow
5. Patients with > Grade 1 peripheral neuropathy per Common Terminology Criteria for
Adverse Events (CTCAE)
6. Patients with active or chronic corneal disorders, history of corneal transplantation,
or active ocular conditions requiring ongoing treatment/monitoring, such as
uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal
injections, active diabetic retinopathy with macular edema, macular degeneration,
presence of papilledema, and /or monocular vision
7. Patients with serious concurrent illness or clinically relevant active infection,
including, but not limited to the following:
1. Active hepatitis B or C infection (whether or not on active antiviral therapy)
2. Human immunodeficiency virus (HIV) infection
3. Active cytomegalovirus infection
4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks
prior to the first dose of MIRV
Note: Testing at screening is not required for the above infections unless clinically
indicated
8. Patients with a history of multiple sclerosis (MS) or other demyelinating disease
and/or Lambert-Eaton syndrome (paraneoplastic syndrome)
9. Patients with clinically significant cardiac disease including, but not limited to,
any of the following:
1. Myocardial infarction = 6 months prior to first dose
2. Unstable angina pectoris
3. Uncontrolled congestive heart failure (New York Heart Association > class II)
4. Uncontrolled = Grade 3 hypertension (per CTCAE)
5. Uncontrolled cardiac arrhythmias
10. Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to
enrollment
11. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)
12. Patients with a previous clinical diagnosis of noninfectious interstitial lung disease
(ILD), including noninfectious pneumonitis
13. Patients requiring use of folate-containing supplements (eg, folate deficiency)
14. Patients with prior hypersensitivity to monoclonal antibodies (mAb)
15. Women who are pregnant or breastfeeding
16. Patients who received prior treatment with MIRV or other FRa-targeting agents
17. Patients with untreated or symptomatic central nervous system (CNS) metastases
18. Patients with a history of other malignancy within 3 years prior to enrollment.
Note: patients with tumors with a negligible risk for metastasis or death (eg,
adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or
carcinoma in situ of the cervix or breast) are eligible
19. Prior known hypersensitivity reactions to study drugs and/or any of their excipients
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/07/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/11/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
106
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal North Shore Hospital - St. Leonards
Query!
Recruitment hospital [2]
0
0
ICON Cancer Care - Auchenflower
Query!
Recruitment hospital [3]
0
0
Peninsula and South Eastern Haematology & Oncology Group - Frankston
Query!
Recruitment hospital [4]
0
0
St John of God Subiaco Hospital - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [2]
0
0
4066 - Auchenflower
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [4]
0
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nevada
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Jersey
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Washington
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Wisconsin
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Bruxelles
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Luxembourg
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Gent
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Leuven
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Namur
Query!
Country [26]
0
0
Bulgaria
Query!
State/province [26]
0
0
Sofia
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Prague
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Baden-Württemberg
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Niedersachsen
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Essen
Query!
Country [31]
0
0
Ireland
Query!
State/province [31]
0
0
Leinster
Query!
Country [32]
0
0
Ireland
Query!
State/province [32]
0
0
Munster
Query!
Country [33]
0
0
Ireland
Query!
State/province [33]
0
0
Dublin
Query!
Country [34]
0
0
Israel
Query!
State/province [34]
0
0
Haifa
Query!
Country [35]
0
0
Israel
Query!
State/province [35]
0
0
Jerusalem
Query!
Country [36]
0
0
Israel
Query!
State/province [36]
0
0
Kfar Saba
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Ramat Gan
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Rehovot
Query!
Country [39]
0
0
Israel
Query!
State/province [39]
0
0
Safed
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Bologna
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Brescia
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Candiolo
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Catania
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Milano
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Napoli
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Perugia
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Roma
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Silesia
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Warminsko-Mazurskie
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Lódzkie
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Barcelona
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Castellana
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Galicia
Query!
Country [54]
0
0
Spain
Query!
State/province [54]
0
0
Córdoba
Query!
Country [55]
0
0
Spain
Query!
State/province [55]
0
0
Girona
Query!
Country [56]
0
0
Spain
Query!
State/province [56]
0
0
Madrid
Query!
Country [57]
0
0
Spain
Query!
State/province [57]
0
0
Murcia
Query!
Country [58]
0
0
Spain
Query!
State/province [58]
0
0
Sabadell
Query!
Country [59]
0
0
Spain
Query!
State/province [59]
0
0
Valencia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
ImmunoGen, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine
(MIRV) in patients with platinum-resistant high-grade serous epithelial ovarian cancer,
primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate
Receptor-Alpha (FRa). Patients will be, in the opinion of the Investigator, appropriate for
single-agent therapy for their next line of therapy. All patients will receive single-agent
MIRV at 6 mg/kg adjusted ideal body weight administered on Day 1 of every 3-week cycle.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04296890
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Michael Method, MPH, MBA
Query!
Address
0
0
ImmunoGen, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04296890
Download to PDF